跳至主要内容
临床试验/NCT06101069
NCT06101069
招募中
不适用

Development of Magnetic Resonance Fingerprinting for Characterization of Brain Tumors After Radiotherapy

Case Comprehensive Cancer Center2 个研究点 分布在 1 个国家目标入组 60 人2024年10月14日

概览

阶段
不适用
干预措施
MRF in conjunction with IVIM MRI without contrast
疾病 / 适应症
未指定
发起方
Case Comprehensive Cancer Center
入组人数
60
试验地点
2
主要终点
Comparison of T1 relaxation times
状态
招募中
最后更新
2个月前

概览

简要总结

The purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short scan time of 5 min for viewing the entire brain. This is an advanced quantitative assessment of brain tissues. This method is being applied with IVIM MRI to be able to tell the difference between a brain with radiation necrosis and a brain with tumor recurrence. Participants will consist of individuals who have received radiation therapy in the past and were diagnosed with radiation necrosis, individuals with recurrent tumors, individuals with previously untreated tumors, and healthy individuals who have no brain diseases and have not had radiation treatment to the brain. Participants will undergo an MRI scan at a one-time research study visit; no extra tests or procedures will be required for this research study.

The primary objectives of this study are:

  • To demonstrate the clinical feasibility of combining MRF with state-of-the-art parallel imaging techniques to achieve high-resolution quantitative imaging within a reasonable scan time of 5 min for whole brain coverage.
  • To apply the developed quantitative approach in combination with IVIM MRI for differentiation of tumor recurrence and radiation necrosis.
  • To investigate the effect of radiation dose on the development of radiation necrosis and tumor recurrence.

详细描述

Although Stereotactic radiosurgery (SRS) is utilized as an effective treatment method, after several months to over 1 year following SRS, 33% of treated brain metastases increase in size on imaging, which is suspicious for tumor progression. However, based on findings in follow-up biopsies, the majority of newly detected metastases on imaging are radiation treatment effects instead of active tumor. So far, the only gold standard to differentiate active tumor and radiation necrosis is surgical resection for pathologic confirmation, which is invasive, not favored for poor surgical candidates, and should be avoided in cases of necrosis. The existing clinical imaging techniques have poor sensitivity or specificity in differentiating these two types of tissues. Recently, a novel MRI data acquisition approach, namely MR Fingerprinting (MRF), has been introduced for the simultaneous measurement of multiple important parameters in a single MRI scan. In addition, quantitative diffusion MRI, such as the intravoxel incoherent motion (IVIM) technique, can provide a noninvasive and powerful tool to quantify microstructural information by measuring water diffusion and microcirculation perfusion in vivo. This study aims to demonstrate the clinical feasibility of combining MRF with state-of-the-art parallel imaging techniques to achieve high-resolution quantitative imaging within a reasonable scan time of 5 min for whole brain coverage. It also aims to apply the developed quantitative approach in combination with IVIM MRI for the differentiation of tumor recurrence and radiation necrosis. The multi-parametric quantitative measures developed in this study could establish a new fundamental biomarker for the diagnosis and monitoring of brain tumors.

注册库
clinicaltrials.gov
开始日期
2024年10月14日
结束日期
2026年9月1日
最后更新
2个月前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Sponsor

入排标准

入选标准

  • for Healthy Participants:
  • No history of cerebrovascular disease.
  • No cognitive impairments.
  • Able to provide informed consent.
  • Inclusion Criteria for Participants with Brain Tumors:
  • Biopsy-proven cases of developed recurrent tumor or radiation necrosis, OR
  • a. PET identified with developed recurrent tumor or radiation necrosis. OR
  • b. Highly suspicious case with developed recurrent tumor or radiation necrosis confirmed by tumor board, attending physician or surgeon.
  • ECOG performance status 0-
  • Life expectancy \> 6 months.

排除标准

  • Pregnant women OR lactating women
  • Participants with ferromagnetic or otherwise non-MRI compatible aneurysm clips.
  • Participants who cannot go into the MRI scanner due to metal implants and other medical conditions.
  • The presence of an implanted medical device that is not MRI-compatible, including, but not limited to: pacemaker, defibrillator.
  • Participants with contraindications for MRI due to embedded foreign metallic objects such as bullets, shrapnel, metalwork fragments, or other metallic material.
  • Known history of severe claustrophobia.
  • Participants unable to lay still in the scanner for 30 minutes at a time.

研究组 & 干预措施

Participants with Primary Gliomas

The MRI scans (MRF and IVIM) will be performed on participants with newly developed, untreated primary gliomas prior to any therapy implementation, surgical biopsy, or resection. For the participants undergoing surgical biopsy or resection after the MRI scans, the findings from the analysis of pathological biopsied specimen will serve as pathological confirmation for the MRI imaging findings

干预措施: MRF in conjunction with IVIM MRI without contrast

Healthy Volunteer Participants

Healthy volunteers will be recruited to evaluate the capability of MRF in conjunction with intravoxel incoherent motion (IVIM) MRI and serve as healthy control data to compare with the participant data.

干预措施: MRF in conjunction with IVIM MRI without contrast

Participants with Radiation Necrosis

The MRI scans (MRF and IVIM) will be performed on participants with newly developed necrosis prior to any further therapy implementation, surgical biopsy, or resection. For the participants undergoing surgical biopsy or resection after the MRI scans, the findings from the analysis of pathological biopsied specimen will serve as pathological confirmation for the MRI imaging findings

干预措施: MRF in conjunction with IVIM MRI without contrast

Participants with Tumor Recurrence

The MRI scans (MRF and IVIM) will be performed on participants with newly developed recurrent prior to any further therapy implementation, surgical biopsy, or resection. For the participants undergoing surgical biopsy or resection after the MRI scans, the findings from the analysis of pathological biopsied specimen will serve as pathological confirmation for the MRI imaging findings

干预措施: MRF in conjunction with IVIM MRI without contrast

Participants with Brain Metastases

The MRI scans (MRF and IVIM) will be performed on participants with newly developed, untreated brain metastases prior to any therapy implementation, surgical biopsy, or resection. For the participants undergoing surgical biopsy or resection after the MRI scans, the findings from the analysis of pathological biopsied specimen will serve as pathological confirmation for the MRI imaging findings

干预措施: MRF in conjunction with IVIM MRI without contrast

结局指标

主要结局

Comparison of T1 relaxation times

时间窗: Within the total 30-45 minute scan time

The primary objective is to use MRF and IVIM MRI to demonstrate clinical feasibility and differentiation of tumor recurrence and radiation necrosis. This will be measured by the 3D-MRF T1 relaxation times. The difference in mean T1 between each cohort of participants will be measured.

Comparison of T2 relaxation times

时间窗: Within the total 30-45 minute scan time

The primary objective is to use MRF and IVIM MRI to demonstrate clinical feasibility and differentiation of tumor recurrence and radiation necrosis. This will be measured by the 3D-MRF T2 relaxation times. The difference in mean T2 between each cohort of participants will be measured.

Comparison of MRF imaging tool in different participant populations

时间窗: Within the total 30-45 minute scan time

The objective is to compare the effects of radiation dose on development of radiation and necrosis and tumor recurrence by comparing participants in all cohorts (healthy participants with no brain disease, participants with brain tumors (treated), participants with brain metastases or primary gliomas (previously untreated)). The predictive ability will be assessed by comparing univariable ROC analysis, quantified using area under the curve (AUC).

Comparison of proton density maps

时间窗: Within the total 30-45 minute scan time

The primary objective is to use MRF and IVIM MRI to demonstrate clinical feasibility and differentiation of tumor recurrence and radiation necrosis. This will be measured by comparing the MRF proton density maps of each cohort of participants. This will be compared using a t-test.

Comparison of blood perfusion in brain tissues

时间窗: Within the total 30-45 minute scan time

The primary objective is to use MRF and IVIM MRI to demonstrate clinical feasibility and differentiation of tumor recurrence and radiation necrosis. This will be measured by comparing the perfusion parameters measured by the IVIM method between the three cohorts of participants. This will be compared using a t-test.

Comparison of water diffusion in brain tissues

时间窗: Within the total 30-45 minute scan time

The primary objective is to use MRF and IVIM MRI to demonstrate clinical feasibility and differentiation of tumor recurrence and radiation necrosis. This will be measured by comparing the diffusion parameters measured by the IVIM method between the three cohorts of participants. This will be compared using a t-test.

研究点 (2)

Loading locations...

相似试验